Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04157335 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 295
- Enrollment target
NCT04157335 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 295 participants.
The verdict
NCT04157335, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 295 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.
Interventions
- BIOLOGICAL Benralizumab 30 mg
- BIOLOGICAL Matched placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2019-11-25 |
| Est. Completion | 2025-04-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04157335
The ClinicalTrials.gov registry entry for NCT04157335 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Benralizumab 30 mg is the first listed.
NCT04157335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04157335 about?
NCT04157335 is a clinical study titled "Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)". This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.
What is the current status of trial NCT04157335?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2019-11-25. Estimated completion is 2025-04-07.
What interventions are being tested in trial NCT04157335?
The interventions under investigation include: Benralizumab 30 mg (BIOLOGICAL), Matched placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT04157335?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.